Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
PHASE3
The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (F...
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
PHASE2
Investigators are trying to find better treatments for people with HIV-1. I...
Status
Active Not Recruiting
Location
Zuckerberg San Francisco General Hospital and Trauma Center ( Site 4107)
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
PHASE2
This is a randomized, controlled, double-blind, study to evaluate the safet...
Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)
PHASE2
This is a phase 2, single-group, multi-site, open-label study of an islatra...